calcium phosphate/necrosis

1. Study design: randomly assigned, cross-over study. 2. Patient number: 60. 3. Inclusion criteria: stable patients end-stage renal disease who were older than 20 years and received thrice-weekly standard hemodialysis for more than 3 months were recruited. 4. Exclusion criteria: active systemic

Recruitment will be a prospective study in patients with body mass index (BMI) of 23.5-30 kg/m2, aged between 18 and 65 years old. Each patient will be preoperatively screened (including psychologist assessment) and evaluated by the study multidisciplinary team before recruitment. The study will

Study background and rationale Receptor activator of nuclear factor-κB (RANK), RANK ligand (RANKL) and its decoy receptor osteoprotegerin (OPG) play key roles in regulating bone turnover. They are involved in the mechanism of "crosstalk" between osteoblasts and osteoclasts. After binding with RANK,

An estimated 10% of closed fractures and between 35-45% in cases of open fractures, are at risk of developing a delay in the process of consolidation or a complete failure of it (pseudoarthrosis) depending on location , severity of trauma on bone, soft tissue and vascular structures Some of these

Comparative study including - 20 consecutive patients with Martorell HYTILU - 10 consecutive patients with Calciphylaxis (calcific uremic arteriolopathy) - 20 patients with venous ulcer The following parameters are measured in the blood serum: White blood count; c-reactive protein; creatinine;

Cardiovascular diseases (CVD) are the main causes of death and hospitalization in patients affected by ESRD . The risk of death from CVD is already detectable in the early steps of chronic renal failure and it is from 20 to 30 times higher than in the general population. In ESRD patients the

Overall study design This is a single-center randomized placebo control study on 60 prevalent PD patients. Recruitment phase will take up to 12 months, and the study phase will be 1 year. Study code will only be revealed at the end of the study period or if patients develop serious adverse